[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635759":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":26,"locations":36,"responsibleParty":50,"collaborators":19,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":75,"whyStopped":19,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Senyo Health app","EXPERIMENTAL","Patients will utilize the Senyo Health app daily, for 12 weeks",[13],"Other: Senyo Health App",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Senyo Health App","The Senyo Health app includes asynchronous cognitive behavioral therapy (CBT) modules, contingency management, behavioral activation, and an interface to interact with the care manager for support in treating the comorbidities of bipolar disorder and substance use disorder.\n\nPatients will engage with the app daily and have weekly check-in visits with the care manager. After the initial 12 week intervention phase, subjects will be followed for 1 year.",[9],null,[21,24],{"name":22,"affiliation":5,"role":23},"Mark A. Frye, MD","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":5,"role":23},"Tyler S. Oesterle, MD, MPH",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":19,"email":31},"Kelsey Tuen","CONTACT","507-284-2088","tuen.kelsey@mayo.edu",{"name":33,"role":29,"phone":34,"phoneExt":19,"email":35},"Bryce Leatherman","5074222079","leatherman.bryce@mayo.edu",[37],{"facility":38,"status":19,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":19},"Mayo Clinic in Rochester","Rochester","Minnesota","55905","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-92.4699,44.02163,{"lat":48,"lon":47},{"type":23,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Mark Frye","Principal Investigator","100635759","senyo-health-app---comorbid-alcohol-use-disorder-treatment-in-individuals-with-bipolar-disorder-using-a-telehealth-collaborative-care-platform-100635759",false,"NCT07556861","Senyo Health App - Comorbid Alcohol Use Disorder Treatment in Individuals With Bipolar Disorder Using a Telehealth Collaborative Care Platform","Inclusion Criteria:\n\n1. Age\\>=18 years;\n2. History of bipolar I disorder, bipolar II disorder, or schizoaffective disorder of the bipolar type. Can be clinical diagnosis\n3. Ability to read, write, and understand English;\n4. Minimum DAST (1+) or AUDIT-C score (3+)\n5. Access and willingness to use a mobile device for asynchronous (text) and synchronous (video) engagement with care;\n6. Eligibility determined by ASAM Assessment as completed by a LADC.\n\nExclusion Criteria:\n\n1. Inability to actively participate in and learn from psychotherapeutic interaction based on clinical evaluation and clinical judgment;\n2. Needing a higher level of mental health care as demonstrated by ASAM\\[36\\] assessment; - completed by LADC or MD investigators\n3. Already admitted into or about to initiate treatment in another addiction treatment program.\n4. Currently attending High School. (can be 18 though)\n5. Pregnancy confirmed by self-report\n6. Inability to provide written informed consent.\n7. Inability to understand English.\n8. Clinically unstable medical disease.\n9. Otherwise excluded for administrative reasons and\u002For clinician judgment.","ALL","18 Years",{"count":62,"type":63},40,"ESTIMATED","INTERVENTIONAL",[66],"NA","The purpose of this study is to examine the effectiveness of a digital integrated behavioral health (IBH) platform in improving alcohol use outcomes, including treatment retention and substance use frequency and severity in patients with Bipolar Disorder.",[69],"Bipolar Disorder",[71,72,73,74],"Bipolar","Substance Use","SUD","Alcohol","NOT_YET_RECRUITING","2026-07-30",{"date":78,"type":79},"2026-07-31","ACTUAL",{"date":81,"type":63},"2026-09-16",{"date":83,"type":63},"2029-01-20",{"name":5,"class":6},1]